These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride. Stockler-Ipsiroglu S; Yuskiv N; Salvarinova R; Apatean D; Ho G; Cheng B; Giezen A; Lillquist Y; Ueda K Mol Genet Metab; 2015 Mar; 114(3):409-14. PubMed ID: 25497838 [TBL] [Abstract][Full Text] [Related]
29. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride. Douglas TD; Ramakrishnan U; Kable JA; Singh RH Health Qual Life Outcomes; 2013 Dec; 11():218. PubMed ID: 24373161 [TBL] [Abstract][Full Text] [Related]
30. Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial. Eshraghi P; Noroozi Asl S; Bagheri S; Chalak V J Pediatr Endocrinol Metab; 2019 Aug; 32(8):885-888. PubMed ID: 31237861 [TBL] [Abstract][Full Text] [Related]
31. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791 [TBL] [Abstract][Full Text] [Related]
32. Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria. Michals-Matalon K Expert Opin Investig Drugs; 2008 Feb; 17(2):245-51. PubMed ID: 18230057 [TBL] [Abstract][Full Text] [Related]
33. Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria. Rohr F; Wessel A; Brown M; Charette K; Levy HL Mol Genet Metab; 2015 Jan; 114(1):25-8. PubMed ID: 25467057 [TBL] [Abstract][Full Text] [Related]
34. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488 [TBL] [Abstract][Full Text] [Related]
36. Spotlight on sapropterin in primary hyperphenylalaninemia. Sanford M; Keating GM BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172 [TBL] [Abstract][Full Text] [Related]
37. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. Burnett JR IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763 [TBL] [Abstract][Full Text] [Related]